While Trump spent much of his nearly two-hour speech in Michigan ’s Grand Rapids hurling insults and profanities at his ...

Ashby Kilgore was a bit apprehensive when she retired after 46 years in the public school system. “It was like, ‘What the ...

Hims & Hers' strong Q3 results and 77% y/y revenue growth demonstrate its robust business, justifying a continued strong buy ...

Hims & Hers Health, Inc. ( (HIMS) ) has released its Q3 earnings. Here is a breakdown of the information Hims & Hers Health, Inc.

Compounded GLP-1s are essentially copies of popular weight loss medications made by manufacturers such as Novo Nordisk and Eli Lilly. Hims & Hers CEO Andrew Dudum said during the company's third ...

Reports Q3 revenue $401.6M, consensus $382.2M. “Improving momentum in both the Hims and Hers brands delivered another strong quarter of ...

The U.S. stock market experienced a slight downturn on Monday, with the S&P 500 index dipping approximately 0.3%. The Dow ...

The results come as those drugs, like Wegovy and Ozempic, explode in popularity, leading to shortages as well as greater competition. Executives on Monday said those supply constraints were "not ...

With a 77% revenue increase and a growing subscriber base, Hims & Hers Health Inc (HIMS) continues to innovate in ...

Telehealth firm Hims & Hers Health said on Monday it plans to bring a generic version of Novo Nordisk's diabetes drug, liraglutide, to its platform in 2025.

Hims & Hers Health raised its full-year outlook after it swung to a profit in the third quarter boosted by a tax benefit and consumer demand for weight-loss drugs.

Hims Hers Health Inc (NYSE:HIMS) reported third-quarter earnings that surpassed analyst expectations and raised its full-year ...